GlassScriptPhysician profile
Molly Davis
NPI 1467114322
$3,452.58
in general payments reported to CMS, 2019-2025
40 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 91% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $535 · 2024: $1,362 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,296.64 |
| Education | $155.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $266.79 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $243.94 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $198.80 | 2023-2025 | Enhertu, Datroway |
| Pfizer INC. | $162.87 | 2023-2025 | |
| Gilead Sciences, INC. | $160.46 | 2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $157.59 | 2023-2025 | Lynparza, Calquence, Imfinzi |
| Abbvie INC. | $150.98 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $148.86 | 2025 | |
| Stemline Therapeutics INC. | $129.70 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $127.96 | 2023-2025 | Iclusig, Ninlaro |
| Blueprint Medicines Corporation | $120.10 | 2024-2025 | Ayvakit |
| Array Biopharma INC | $117.87 | 2024-2025 | Mektovi, Braftovi, Xalkori |
| Celgene Corporation | $100.01 | 2024-2025 | Reblozyl |
| Pharmaessentia USA Corporation | $99.48 | 2023-2025 | Besremi |
| Karyopharm Therapeutics INC. | $96.90 | 2023-2025 | Xpovio |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $87.62 | 2023-2024 | Bavencio, Tepmetko |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.23 | 2023-2024 | Gilotrif |
| Bayer Healthcare Pharmaceuticals INC. | $81.57 | 2024-2025 | |
| Eisai INC. | $79.06 | 2024 | |
| Taiho Oncology, INC. | $77.75 | 2023-2025 | |
| Genentech USA, INC. | $73.62 | 2024-2025 | Tecentriq, Venclexta, Polivy |
| Exelixis INC. | $72.87 | 2024-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $62.47 | 2024-2025 | Jemperli, Ojjaara |
| Seagen INC. | $58.94 | 2023 | Tukysa, Adcetris |
| Acadia Pharmaceuticals INC | $53.59 | 2024 | Nuplazid |
| Agios Pharmaceuticals, INC. | $45.70 | 2025 | Pyrukynd |
| Astellas Pharma US INC | $44.80 | 2023-2024 | Xtandi, Padcev |
| Immunocore Limited | $38.24 | 2024-2025 | Kimmtrak |
| Regeneron Healthcare Solutions, INC. | $32.46 | 2025 | Libtayo |
| Sobi, INC | $30.40 | 2024 | |
| Jazz Pharmaceuticals INC. | $27.78 | 2023 | |
| Amgen INC. | $27.17 | 2023 | Xgeva, Nplate |
| Syndax Pharmaceuticals, INC. | $27.14 | 2025 | |
| Myriad Genetic Laboratories, INC. | $27.01 | 2025 | Myrisk |
| Mirati Therapeutics, INC. | $26.70 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $24.92 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $24.67 | 2025 | Opdivo |
| Dendreon Pharmaceuticals LLC | $21.20 | 2024 | Provenge |
| Immunogen, INC. | $21.12 | 2023 | Elahere |
| Puma Biotechnology, INC. | $19.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.